MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Income Overview

Revenue
$9,512K
Net Income
-$3,782K
Net Profit Margin
-39.76%
Unit: Thousand (K) dollars
Revenue Breakdown
    • Consumables Revenue
    • Capital Revenue
    • Engineering Revenue
    • Product And Service Other
Revenue Breakdown
    • Therapeutics
    • Diagnostics
    • Development Services
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net revenue
9,512
8,799
10,471
8,095
Cost of revenue
3,471
3,315
3,301
2,659
Gross profit
6,041
5,484
7,170
5,436
General and administrative
5,379
5,413
6,172
5,900
Research and development
1,070
1,154
1,643
1,784
Selling and marketing
3,675
3,817
4,519
4,358
Impairment expense
-
-
0
-
Loss from operations
-4,083
-4,900
-5,164
-6,606
Interest income
404
455
515
561
Loss on disposal of assets
-2
-15
-25
-36
Other expense
-43
-26
-48
-13
Foreign exchange (loss) income
-15
-9
-22
-46
Loss before income taxes
-3,739
-4,495
-4,744
-6,140
Income tax expense (benefit)
26
39
-214
-19
Net loss
-3,765
-4,534
-4,530
-6,121
Unrealized loss, change in fair value of available-for-sale securities, net of tax
-5
-43
-8
34
Change in foreign currency translation
-12
-14
-25
-18
Net loss and comprehensive loss
-3,782
-4,591
-4,563
-6,105
Basic EPS
0
0
-0.005
-0.01
Diluted EPS
-
0
-0.005
-0.01
Basic Average Shares
979,949,668
979,949,668
979,949,668
979,949,668
Diluted Average Shares
-
-
979,949,668
979,949,668
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

Net loss andcomprehensive loss-$3,782K (48.57%↑ Y/Y)Therapeutics$5,112K Diagnostics$1,175K Development Services$362K Therapeutics$1,626K Diagnostics$210K Development Services$3K Revenue From ContractWith Customer...$979K Development Services$29K Therapeutics$16K Net loss-$3,765K (49.11%↑ Y/Y)Change in foreigncurrency translation-$12K (-121.82%↓ Y/Y)Unrealized loss, change infair value of...-$5K (50.00%↑ Y/Y)Consumables Revenue$6,649K Capital Revenue$1,839K Engineering Revenue$979K Product And ServiceOther$45K Loss before incometaxes-$3,739K (49.38%↑ Y/Y)Income tax expense(benefit)$26K (116.67%↑ Y/Y)Interest income$404K (-35.77%↓ Y/Y)Net revenue$9,512K (36.59%↑ Y/Y)Loss from operations-$4,083K (49.18%↑ Y/Y)Gross profit$6,041K (29.47%↑ Y/Y)Other expense-$43K (-10.26%↓ Y/Y)Foreign exchange (loss)income-$15K (-125.86%↓ Y/Y)Loss on disposal ofassets-$2K (-300.00%↓ Y/Y)Cost of revenue$3,471K (51.04%↑ Y/Y)General andadministrative$5,379K (-12.71%↓ Y/Y)Selling and marketing$3,675K (-21.02%↓ Y/Y)Research and development$1,070K (-43.27%↓ Y/Y)

Zomedica Corp. (ZOMDF)

Zomedica Corp. (ZOMDF)